Director/PDMR Shareholding

Name of the Issuer:

Hikma Pharmaceuticals PLC

State whether the notification relates to (i) a transaction notified in accordance with DTR 3.1.2 R, (ii) a disclosure made in accordance with LR 9.8.6R(1) or (iii) a disclosure made in accordance with section 793 of the Companies Act (2006):

DTR 3.1.2 R

Name of person discharging managerial responsibilities/director:

Samih Darwazah, Said Darwazah, Mazen Darwazah and Ali Al-Husry

State whether notification relates to a person connected with a person discharging managerial responsibilities/ director named in 3 and identify the connected person:

Yes: Darhold Limited

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest:

Beneficial interest Darhold Limited

Description of shares (including class), debentures or derivatives or financial instruments relating to shares:

Ordinary Shares

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them:

PNB Paribas Securities Services account for and on behalf of CSFB

State the nature of the transaction:

The transaction comprises a cap and floor transaction involving

A variable forward sale of up to 3,000,000 Ordinary Shares

A stock loan of up to 3,000,000 Ordinary Shares

A pledge over 3,500,000 Ordinary Shares in support of a loan

Number of shares, debentures or financial instruments relating to shares acquired:

None

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage):

N/A

Number of shares, debentures or financial instruments relating to shares disposed:

Up to 3,000,000 ordinary shares may be disposed of pursuant to the variable forward sale and Darhold Limited may elect in its sole discretion to settle the variable forward sale in cash instead of shares

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage):

The variable forward sale and stock loan relates to up to approximately 1.58 per cent. of all ordinary shares

The share pledge relates to approximately 1.84 per cent. of all ordinary shares. In connection with this transaction a corresponding number of ordinary shares have been released from pre-existing pledges.

Price per share or value of transaction:

The variable forward sale price will be determined by the market price at the time of settlement, subject to:

A minimum (floor) price of 421 pence per ordinary share; and

A maximum (cap) price. of 561 pence per ordinary share.

Date and place of transaction:

Documents executed on 14 October 2009 and pricing finalised on 13 November 2009, London

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage):

57,183,028 - 29.9 per cent.

Date issuer informed of transaction:

16 November 2009

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

Date of grant

Period during which or date on which exercisable

Total amount paid (if any) for grant of the option

Description of shares or debentures involved (class and number)

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

Total number of shares or debentures over which options held following notification

Any additional information

Name of contact and telephone number for queries

Name of authorised official or issuer responsible for making notification

Date of notification 18 November 2009